Reply To: New BRAF/MEK inhibitors coming to market

[Samantha Guild]

We were so excited to hear about the approval! We have had several patients who have been waiting for the approval due to intolerability with Dabrafenib and Tramatenib. We just now need to wait for insurance to update their system to be able to get access to these drugs. The main issue is going to be the same as we see with the other targeted therapies which is high copays for our patients with Medicare part D. Finding sources or assistance programs to help with patients donut holes is always difficult.